GlassScriptPhysician profile
Dorian R Mann
NPI 1821440215
$6,668.87
in general payments reported to CMS, 2019-2025
43 companies · $2,670 in 2025
The $2,670 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $50.68 · 2022: $61.02 · 2023: $1,287 · 2024: $2,600 · 2025: $2,670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,382 · Consulting Fee: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,382.17 |
| Consulting Fee | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,264.57 | 2023-2025 | |
| Pfizer INC. | $814.66 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $813.58 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $536.68 | 2023-2025 | Prolia, Otezla, Repatha |
| Novo Nordisk INC | $348.19 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Neurocrine Biosciences, INC. | $293.96 | 2023-2025 | Ingrezza, Ongentys |
| Sumitomo Pharma America, INC. | $251.37 | 2023-2025 | Gemtesa |
| Lilly USA, LLC | $205.71 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $202.96 | 2023-2025 | |
| Astellas Pharma US INC | $172.08 | 2024-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $171.67 | 2024-2025 | |
| Verona Pharma, INC. | $135.55 | 2025 | Ohtuvayre |
| Inari Medical, INC. | $122.10 | 2023-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Dexcom, INC. | $114.77 | 2024-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $107.28 | 2023-2025 | Arexvy, Trelegy Ellipta, Shingrix |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $102.60 | 2023-2025 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.01 | 2023-2025 | Jardiance |
| Medtronic, INC. | $71.39 | 2023-2025 | Intellis Adaptivestim |
| Otsuka America Pharmaceutical, INC. | $70.82 | 2024-2025 | Rexulti |
| Exact Sciences Corporation | $67.92 | 2023-2025 | Cologuard Collection Kit |
| Shield Therapeutics INC | $64.55 | 2024-2025 | |
| Acadia Pharmaceuticals INC | $59.04 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $56.43 | 2024-2025 | Zoryve |
| Phathom Pharmaceuticals, INC. | $51.85 | 2024-2025 | Voquezna |
| Eisai INC. | $42.53 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $40.87 | 2023-2025 | Belsomra, Capvaxive, Gardasil 9 |
| Lundbeck LLC | $36.89 | 2025 | Rexulti |
| Axsome Therapeutics, INC. | $36.41 | 2025 | Symbravo |
| Antares Pharma, INC. | $34.23 | 2024-2025 | Xyosted |
| Tolmar, INC. | $33.61 | 2025 | Jatenzo |
| Ani Pharmaceuticals, INC. | $31.26 | 2025 | Purified Cortrophin Gel |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $28.81 | 2025 | Caplyta |
| Edwards Lifesciences Corporation | $28.44 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Recor Medical INC | $24.82 | 2025 | Paradise Ultrasound Renal Denervation System |
| Janssen Pharmaceuticals, INC | $21.75 | 2025 | Spravato |
| Indivior INC. | $18.94 | 2021 | |
| Scpharmaceuticals INC. | $16.49 | 2025 | |
| Vanda Pharmaceuticals INC. | $15.47 | 2025 | Fanapt, Hetlioz |
| Esperion Therapeutics, INC. | $15.19 | 2025 | Nexletol |
| Abbott Laboratories | $14.45 | 2024 | Octrode |
| Xeris Pharmaceuticals, INC. | $14.22 | 2023 | Gvoke Hypopen |
| Tonix Medicines, INC. | $14.09 | 2025 | Tonmya |
| Genentech USA, INC. | $8.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dorian Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.